Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers

Oncology Reports

Volumn 29, Issue 6, 2013, Pages 2415-2421

  Prochazka, Pavel ^a,b   Hrabeta, Jan ^a   Vicha, Ales ^a   Cipro, Simon ^a   Stejskalova, Eva ^a   Musil, Zdenek ^c   Vodicka, Pavel ^b,c   Eckschlager, Tomas ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

2p gain; Cisplatin resistance; Fluorescent in situ hybridization; High risk neuroblastoma cell line; Multiplex ligation dependent probe amplification; MYCN amplification; MYCN expression

Indexed keywords

CISPLATIN; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN SK N AS; CELL STRAIN UKF NB 3; CELL STRAIN UKF NB 4; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; INTERPHASE; METAPHASE; MOLECULARLY TARGETED THERAPY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEUROBLASTOMA CELL; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; V MYC MYELOCYTOMATOSIS VIRAL RELATED ONCOGENE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS;

EID: 84876239552     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2383     Document Type: Article

References (42)

1. Schwab M: MYCN in neuronal tumours. Cancer Lett 204: 179-187, 2004.
2. Kyo Y, Tanaka T, Hayashi K, et al: Identification of therapy-sensitive and therapy-resistant neuroblastoma subtypes in stages III, IVs and IV. Cancer Lett 306: 27-33, 2011.
3. Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348, 2001. (Pubitemid 32467043)
4. Westermark UK, Wilhelm M, Frenzel A and Henriksson MA: The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol 21: 256-266, 2011.
5. Souzaki R, Tajiri T, Teshiba R, et al: The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma. Pediatr Surg Int 27: 231-236, 2011.
6. Ambros PF, Ambros IM, Brodeur GM, et al : International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100: 1471-1482, 2009.
7. Prochazka P, Hrabeta J, Vicha A and Eckschlager T: Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine. Cancer Genet Cytogenet 196: 96-104, 2010.
8. Baumann Kubetzko FB, Di Paolo C, Maag C, et al: The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 25: 1839-1846, 2004. (Pubitemid 39405902)
9. Bian X, Giordano TD, Lin HJ, Solomon G, Castle VP and Opipari AW Jr: Chemotherapy-induced apoptosis of S-type neuroblastoma cells requires caspase-9 and is augmented by CD95/Fas stimulation. J Biol Chem 279: 4663-4669, 2004. (Pubitemid 38199059)
10. Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet 369: 2106-2120, 2007. (Pubitemid 46935947)
11. de Cremoux P, Jourdan-Da-Silva N, Couturier J, et al: Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 48: 311-317, 2007. (Pubitemid 46238522)
12. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216, 2003.
13. Tang XX, Zhao H, Kung B, et al: The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 66: 2826-2833, 2006.
14. Lutz W and Schwab M: In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells. Oncogene 15: 303-315, 1997. (Pubitemid 27370877)
15. Westermann F, Muth D, Benner A, et al: Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9: R150, 2008.
16. Fulda S, Lutz W, Schwab M and Debatin KM: MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 18: 1479-1486, 1999. (Pubitemid 29103635)
17. Porro A, Haber M, Diolaiti D, et al: Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J Biol Chem 285: 19532-19543, 2010.
18. Bell E, Chen L, Liu T, Marshall GM, Lunec J and Tweddle DA: MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 293: 144-157, 2010.
19. Albihn A, Johnsen JI and Henriksson MA: MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107: 163-224, 2010.
20. Gustafson WC and Weiss WA: Myc proteins as therapeutic targets. Oncogene 29: 1249-1259, 2010.
21. Prochazka P, Libra A, Zemanova Z, et al: Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells. Cancer Sci 103: 334-341, 2012.
22. Kotchetkov R, Cinatl J, Blaheta R, et al: Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 104: 36-43, 2003. (Pubitemid 36184144)
23. Poljakova J, Eckschlager T, Hrabeta J, et al: The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol 77: 1466-1479, 2009.
24. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
25. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM and Norris MD: Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54: 5036-5040, 1994. (Pubitemid 24313471)
26. Beiske K, Ambros PF, Burchill SA, Cheung IY and Swerts K: Detecting minimal residual disease in neuroblastoma patients - the present state of the art. Cancer Lett 228: 229-240, 2005. (Pubitemid 41188446)
27. Hogarty MD, Norris MD, Davis K, et al: ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68: 9735-9745, 2008.
28. Ambros PF and Ambros IM; SIOP Europe Neuroblastoma Pathology, Biology and Bone Marrow Group. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37: 492-504, 2001. (Pubitemid 33101388)
29. Valent A, Le Roux G, Barrois M, et al: MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. J Pathol 198: 495-501, 2002. (Pubitemid 35452515)
30. Jeison M, Ash S, Halevy-Berko G, et al: 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics. Am J Pathol 176: 2616-2625, 2010.
31. Spitz R, Hero B, Skowron M, Ernestus K and Berthold F: MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Eur J Cancer 40: 2753-2759, 2004. (Pubitemid 39574728)
32. Cohen N, Betts DR, Rechavi G, Amariglio N and Trakhtenbrot L: Clonal expansion and not cell interconversion is the basis for the neuroblast and nonneuronal types of the SK-N-SH neuroblastoma cell line. Cancer Genet Cytogenet 143: 80-84, 2003. (Pubitemid 36549010)
33. Ambros IM, Brunner B, Aigner G, et al: A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 17: 792-804, 2011.
34. Chan HS, Gallie BL, DeBoer G, et al: MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 3: 1699-1706, 1997. (Pubitemid 27444707)
35. Cohn SL, London WB, Huang D, et al: MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 18: 3604-3613, 2000.
36. Bieche I, Laurendeau I, Tozlu S, et al: Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 59: 2759-2765, 1999. (Pubitemid 29283103)
37. Smith DR and Goh HS: Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene. Clin Cancer Res 2: 1049-1053, 1996. (Pubitemid 26198474)
38. Paffhausen T, Schwab M and Westermann F: Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett 250: 17-24, 2007. (Pubitemid 46483842)
39. Bedrnicek J, Vicha A, Jarosova M, et al: Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Neoplasma 52: 415-419, 2005. (Pubitemid 41406690)
40. van Noesel MM, Pieters R, Voute PA and Versteeg R: The N-myc paradox: N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis. Cancer Lett 197: 165-172, 2003. (Pubitemid 36860006)
41. Wasenius VM, Jekunen A, Monni O, et al: Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer 18: 286-291, 1997. (Pubitemid 27161398)
42. Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S and Fukuzawa M: Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol 30: 1189-1196, 2007.